Selected article for: "case control and control trial"

Author: Kazemi, Asma; Mohammadi, Vida; Aghababaee, Sahar Keshtkar; Golzarand, Mahdieh; Clark, Cain C T; Babajafari, Siavash
Title: Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis
  • Cord-id: tuckrqwv
  • Document date: 2021_3_5
  • ID: tuckrqwv
    Snippet: This systematic review was conducted to summarize and clarify the evidence on the association between 25-hydroxyvitamin-D [25(OH)D] concentrations and coronavirus disease 2019 (COVID-19) risk and outcomes. PubMed, Scopus, and Web of Science databases and Google Scholar were searched up to 26 November 2020. All retrospective and prospective cohort, cross-sectional, case-control, and randomized controlled trial studies that investigated the relation between 25(OH)D and severe acute respiratory syn
    Document: This systematic review was conducted to summarize and clarify the evidence on the association between 25-hydroxyvitamin-D [25(OH)D] concentrations and coronavirus disease 2019 (COVID-19) risk and outcomes. PubMed, Scopus, and Web of Science databases and Google Scholar were searched up to 26 November 2020. All retrospective and prospective cohort, cross-sectional, case-control, and randomized controlled trial studies that investigated the relation between 25(OH)D and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 severity were included. Thirty-nine studies were included in the current systematic review. In studies that were adjusted (OR: 1.77; 95% CI: 1.24, 2.53; I(2): 44.2%) and nonadjusted for confounders (OR: 1.75; 95% CI: 1.44, 2.13; I(2): 33.0%) there was a higher risk of SARS-CoV-2 infection in the vitamin D deficiency (VDD) group. Fifteen studies evaluated associations between VDD and composite severity. In the studies that were adjusted (OR: 2.57; 95% CI: 1.65, 4.01; I(2) = 0.0%) and nonadjusted for confounders (OR: 10.61; 95% CI: 2.07, 54.23; I(2) = 90.8%) there was a higher severity in the VDD group. Analysis of studies with crude OR (OR: 2.62; 95% CI: 1.13, 6.05; I(2): 47.9%), and adjusted studies that used the Cox survival method (HR: 2.35; 95% CI: 1.22, 4.52; I(2): 84%) indicated a significant association of VDD with mortality, while in adjusted studies that used logistic regression, no relation was observed (OR: 1.05; 95% CI: 0.63, 1.75; I(2): 76.6%). The results of studies that examined relations between VDD and intensive care unit (ICU) admission, pulmonary complications, hospitalization, and inflammation were inconsistent. In conclusion, although studies were heterogeneous in methodological and statistical approach, most of them indicated a significant relation between 25(OH)D and SARS-CoV-2 infection, COVID-19 composite severity, and mortality. With regard to infection, caution should be taken in interpreting the results, due to inherent study limitations. For ICU admission, inflammation, hospitalization, and pulmonary involvement, the evidence is currently inconsistent and insufficient.

    Search related documents:
    Co phrase search for related documents
    • active form and acute respiratory infection: 1
    • active form and adaptive immune response: 1, 2, 3
    • active form and logistic regression: 1
    • active form and low concentration: 1, 2, 3
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adjusted relative risk: 1
    • acute ards respiratory distress syndrome and adjustment factor: 1, 2, 3
    • acute ards respiratory distress syndrome and admission measure: 1
    • acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and low concentration: 1
    • acute ards respiratory distress syndrome and lung field: 1, 2, 3
    • acute ards respiratory distress syndrome and lung infiltrate: 1
    • acute ards respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and adjusted relative risk: 1
    • acute phase and admission measure: 1
    • acute phase and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute phase and low concentration: 1, 2, 3
    • acute phase and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9